RGEN NASDAQ
Repligen Corporation
1W: -4.2%
1M: +5.1%
3M: +28.4%
YTD: +10.6%
1Y: +24.6%
3Y: +12.9%
5Y: -43.8%
$181.70
+4.47 (+2.52%)
Weekly Expected Move ±6.0%
$160
$171
$182
$193
$203
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
William Blair refreshes its analyst conviction list
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
Repligen (NASDAQ:RGEN) Hits New 52-Week High – Still a Buy?
Repligen Corporation $RGEN Shares Acquired by Corient Private Wealth LP
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Tidal Investments LLC Raises Holdings in Repligen Corporation $RGEN
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Amundi Trims Stake in Repligen Corporation $RGEN
California State Teachers Retirement System Buys 8,139,821 Shares of Repligen Corporation $RGEN
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
QURE Submits Application for Gene Therapy for Huntington's Disease
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
JAZZ Rises on Updated OS Results From Gastric Cancer Study
William Blair updates its stock Conviction List
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
American Capital Management Inc. Makes New $49.26 Million Investment in Repligen Corporation $RGEN
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
5 Biotech Stocks Worth Adding to Your Portfolio Now
25,992 Shares in Repligen Corporation $RGEN Acquired by Bank of Nova Scotia
J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
B. Metzler seel. Sohn & Co. AG Takes $3.60 Million Position in Repligen Corporation $RGEN
HALO Stock Rises 36% in a Month: Here's What You Should Know
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 Growth
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
Alpine Woods Capital Investors LLC Sells 3,839 Shares of Repligen Corporation $RGEN
Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
Repligen (NASDAQ:RGEN) Shares Gap Up on Better-Than-Expected Earnings
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
American Capital Management Inc. Purchases 22,605 Shares of Repligen Corporation $RGEN
Here are the major earnings before the open Tuesday
Key deals this week: Stripe, IBM, Repligen, LXP Industrial Trust and more
Notable healthcare headlines for the week: Eli Lilly, Molina Healthcare, and Roche in focus
Repligen Corporation $RGEN Shares Purchased by First Trust Advisors LP
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Is Repligen Corporation (RGEN) A Good Stock To Buy Now?
BioLife is said to have drawn takeover interest from Repligen
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift by end of 2027
Repligen Corporation Q1 2026 Earnings Call Summary
Repligen (RGEN) Q1 2026 Earnings Call Transcript
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
Repligen Non-GAAP EPS of $0.48 beats by $0.10, revenue of $194M beats by $1.83M